Biotechnology
Filter News
Found 46,677 articles
-
Calidi Biotherapeutics to Present at Jefferies Healthcare Conference
6/2/2022
Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, today announced that Stephen Thesing, Chief Business Officer, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET.
-
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
6/2/2022
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that its Annual Combined Shareholders General Meeting will be held on June 23, 2022.
-
Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022
6/2/2022
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported that data supporting the role of CCL24 as a therapeutic target for systemic sclerosis (SSc) is being presented in a poster at the EULAR European Congress of Rheumatology this week.
-
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
6/2/2022
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, will host a global webcast to discuss new data from 1st line non-small cell lung cancer (NSCLC) patients participating in its Phase II TACTI-002 trial including an analyst Q&A.
-
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
6/2/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13 at 4:20 p.m. ET / 1:20 p.m. PT in Rancho Palos Verdes, Calif.
-
Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis® LW-02 Column is Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer
6/2/2022
Immunicom, Inc., a privately held clinical-stage biotechnology company with a transformative immuno-oncology platform, presented data from its ongoing clinical investigation [NCT04004910] at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting.
-
Clinical Strategy for Enhancing Affini-T Therapeutics’ Merkel Polyoma Virus TCR Therapy to be Presented at ASCO 2022
6/2/2022
Affini-T Therapeutics, Inc., today announced that the clinical strategy for enhancing the efficacy of its Merkel cell polyomavirus (MCPyV)-specific T cell receptor (TCR) program for the treatment of PD-1 refractory Merkel cell carcinoma (MCC), from its strategic collaboration with Fred Hutchinson Cancer Center, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022.
-
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
6/2/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference.
-
Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
6/2/2022
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 4:00pm ET.
-
The FDA has issued special designations that could improve the lives of millions with recurrent glioblastoma or hemophilia diagnoses.
-
Pfizer intends to sell off its stake when the de-merger occurs and seek the most profitable sale of its share of Haleon to maximize value for company stockholders.
-
Shares of TG Therapeutics are falling fast in Wednesday trading after the U.S. Food and Drug Administration announced it was pulling approval of the cancer drug Ukoniq (umbralisib).
-
In a recent Massachusetts Biotechnology Council survey, 94.2% of respondents reported having difficulty hiring experienced workers.
-
Several new biotech and biopharma companies are sharing their strengths to develop new treatments for high-need diseases diabetes, Alzheimer’s and cancer.
-
BioSpace looks at the challenges faced by the Latinx community in the life sciences, from the origins of the challenges, to educational gain and the importance of mentorship.
-
Sage Therapeutics and partner Biogen shared news that their phase III Skylark study has yielded promising results for women suffering from severe postpartum depression (PPD).
-
Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
6/1/2022
Accutar Biotechnology, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen receptor signaling inhibitors
-
Asher Bio Announces Clinical Trial Collaboration with Merck to Evaluate AB248 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
6/1/2022
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada) for a planned Phase 1a/1b dose escalation and expansion trial to evaluate AB248.
-
Midatech Pharma PLC Announces Fast Track Designation for MTX110 Development
6/1/2022
Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that upon submitting an application to the U.S. Food and Drug Administration its development programme of MTX110 for the treatment of recurrent glioblastoma ("rGBM") has been granted Fast Track designation by the agency.
-
NeuBase to Participate at the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
NeuBase Therapeutics, Inc. announced that company management will present a corporate overview at the Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.